Filing Summary
Business Context and Reporting Period
Pliant Therapeutics, Inc. filed a Form 8-K on June 17, 2022, reporting matters from its Annual Meeting of Stockholders held on June 16, 2022. The filing is corporate-governance related and does not provide financial results for a reporting period.
Key Financial and Operating Metrics
- As of the April 20, 2022 record date, 36,169,468 shares of common stock were outstanding and entitled to vote.
- The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating-financial metrics.
Material Changes Versus the Prior Comparable Period
The filing text does not identify material changes versus a prior period. It reports the results of the 2022 annual stockholder meeting.
Meeting Results, Outlook, and Other Matters
- John Curnutte, M.D., Ph.D., and Smital Shah were elected as Class II directors for three-year terms expiring at the 2025 Annual Meeting.
- Executive compensation was approved on a non-binding advisory basis, with 27,888,784 votes for, 111,574 against, and 8,625 abstentions; broker non-votes totaled 6,124,917.
- Stockholders recommended, on a non-binding advisory basis, that future advisory votes on executive compensation occur every one year: 27,954,029 votes for one year, compared with 29,118 for two years and 21,831 for three years.
- Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2022, with 34,121,601 votes for, 6,315 against, and 5,984 abstentions.
- No other matters were submitted to or voted on.
- The filing contains no financial guidance, business outlook, contingencies, or unusual financial items.
Investor Verification Points
- Verify the director-election vote totals, including 6,124,917 broker non-votes for Proposal 1.
- Confirm the company’s implementation of the stockholder recommendation for annual advisory votes on executive compensation.
- Review subsequent filings for any changes to the board, executive compensation practices, or auditor appointment.
- Consult the company’s periodic financial filings for revenue, cash runway, liquidity, debt, operating losses, and research-program updates not included in this 8-K.